换一批
换一批Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
第一作者：
Anne S,Tsao
第一单位：
Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: astsao@mdanderson.org.
作者：
主题词
老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯甲酰胺类(Benzamides);顺铂(Cisplatin);无病生存(Disease-Free Survival);女(雌)性(Female);谷氨酸盐类(Glutamates);鸟嘌呤(Guanine);人类(Humans);原位杂交, 荧光(In Situ Hybridization, Fluorescence);肺肿瘤(Lung Neoplasms);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);间皮瘤(Mesothelioma);中年人(Middle Aged);哌嗪类(Piperazines);胸膜肿瘤(Pleural Neoplasms);预后(Prognosis);嘧啶类(Pyrimidines);受体, 血小板源生长因子(Receptors, Platelet-Derived Growth Factor);存活率(Survival Rate);治疗结果(Treatment Outcome)
DOI
10.1016/j.cllc.2013.12.008
PMID
24492162
发布时间
2021-10-21
- 浏览68
Clinical lung cancer
197-201页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
